Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21968364 | 0.89 | IDO1 (0.53) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL20180991 | 0.88 | IDO1 (0.51) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL14228549 | 0.85 | IDO1 (0.56) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL6667381 | 0.84 | IDO1 (0.69) | IDO1MAOBTAAR1MAOAACHE | |
| SCHEMBL14972583 | 0.84 | TAAR1 (0.52) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL10378465 | 0.84 | TAAR1 (0.52) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL16920264 | 0.83 | IDO1 (0.58) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL10204837 | 0.83 | IDO1 (0.58) | IDO1MAOBALDH1A1CYP2D6TAAR1 | |
| SCHEMBL8516680 | 0.82 | MAOB (0.55) | IDO1MAOBMAOAACHE | |
| M-Xylene SCHEMBL4808897 | 0.82 | ACHE (0.55) | IDO1MAOBALDH1A1CYP2D6TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | disclosed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | disclosed |
| EP-2248806-A2 | Quinazoline derivatives as tyrosine kinase inhibitors | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-11-10 | — | — | EP | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
| US-7449465-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-11 | — | — | US | disclosed |
| WO-2005012304-A2 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | TP53, NQO2, TOP1 | IDO1 80/4885MAOB 2182/4885ALDH1A1 1393/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | IDO1 224/4885MAOB 1449/4885ALDH1A1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.